CIK 0001604464 · Non-accelerated filer<br>Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460920988
- Phone
- 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $40,883
- in 1 filing
Net +$959,111. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-28 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,900 | $36.13 | $141K | 335,537 |
| 2019-02-28 | MARCUS JOEL S Director | Sale | −62,590 | $36.07 | $2.3M | 7,500 |
| 2019-02-27 | Ciechanover Isaac E. Chief Executive Officer | Sale | −200 | $35.22 | $7K | 343,137 |
| 2019-02-27 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,700 | $36.20 | $134K | 339,437 |
| 2019-02-27 | MARCUS JOEL S Director | Option exercise | +25,000 | $25.15 | $629K | 32,590 |
| 2019-02-27 | MARCUS JOEL S Director | Option exercise | +10,500 | $24.05 | $253K | 43,090 |
| 2019-02-27 | MARCUS JOEL S Director | Option exercise | +5,500 | $15.08 | $83K | 48,590 |
| 2019-02-27 | MARCUS JOEL S Director | Option exercise | +21,500 | $13.20 | $284K | 70,090 |
| 2019-02-27 | MARCUS JOEL S Director | Option exercise · Non-Qualified Stock Option (Right to Buy) | −25,000 | 0 | ||
| 2019-02-27 | MARCUS JOEL S Director | Option exercise · Non-Qualified Stock Option (Right to Buy) | −10,500 | 0 | ||
| 2019-02-27 | MARCUS JOEL S Director | Option exercise · Non-Qualified Stock Option (Right to Buy) | −5,500 | 0 | ||
| 2019-02-27 | MARCUS JOEL S Director | Option exercise · Non-Qualified Stock Option (Right to Buy) | −21,500 | 0 | ||
| 2019-02-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −775 | $39.59 | $31K | 271,943 |
| 2019-02-15 | Ciechanover Isaac E. Chief Executive Officer | Shares withheld for taxes | −1,176 | $40.45 | $48K | 332,243 |
| 2019-02-15 | Porter Derrell SVP, Head of Global Commercial | Option exercise | +4,000 | $14.30 | $57K | 27,597 |
| 2019-02-15 | Porter Derrell SVP, Head of Global Commercial | Sale | −5,909 | $40.00 | $236K | 21,688 |
| 2019-02-15 | Porter Derrell SVP, Head of Global Commercial | Option exercise · Employee Stock Option (Right to Buy) | −4,000 | 109,666 | ||
| 2019-02-12 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,900 | $39.01 | $152K | 342,138 |
| 2019-02-11 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,900 | $38.52 | $150K | 346,038 |
| 2019-02-11 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −13,975 | $38.55 | $539K | 272,718 |
Page 22 of 29 · 569 trades